Infarct Size and Inflammatory Proteins

> Research explainer: This briefing examines verified primary research published 59 days before the briefing date. It is not a same-day research update and does not provide medical advice.

Evidence

This exploratory cohort study evaluated 70 patients with type 1 myocardial infarction who were recruited at Radboud university medical center from the FITTER trial. Infarct size was represented by peak creatine kinase (CK), a surrogate measure used by the investigators, and inflammatory measures were followed during hospitalization and through 12 weeks. The evidence therefore describes associations between an infarct-size proxy and circulating biomarkers in this defined cohort; it is not a direct measurement of injury by cardiac imaging. (pmid:42373877)

Baseline IL-6 concentrations increased progressively across increasing infarct-size strata. The temporal inflammatory trajectories also differed by infarct-size stratum, with an interaction P value below 0.001. A targeted proteomic analysis confirmed differential trajectories across the strata, with an adjusted interaction P value of 0.009. Together, these findings support an association between larger infarct size and a higher systemic inflammatory burden in this cohort. (pmid:42373877)

The proteomic component used Olink’s Target 96 Inflammation panel, making it a focused assessment of inflammatory proteins rather than an unrestricted survey of the whole proteome. Plasma was assessed with this targeted approach at baseline and 12-week follow-up, alongside serial CRP and IL-6 measurements. The panel’s role was to test whether the size-stratified pattern seen in the conventional biomarkers was also evident across its selected inflammatory proteins. (pmid:42373877)

In the small-infarct group, CRP and IL-6 did not show significant changes. Yet the same group showed downregulation of urokinase (uPA) and upregulation of tumor necrosis factor-related weak inducer of apoptosis (TWEAK) and hepatocyte growth factor (HGF). These protein changes were also observed in moderate or large infarct-size groups. Thus, the absence of significant change in the two named conventional markers within the small-infarct stratum did not mean that every measured inflammatory or angiogenesis-related protein was unchanged. (pmid:42373877)

Analysis — Size-Stratified Protein Response

The central proteomics lesson is one of resolution. Grouping patients by an infarct-size surrogate separated a broad inflammatory pattern—progressively higher baseline IL-6 and differing trajectories—from protein-level changes that were present even in the small-infarct group. In this dataset, CRP and IL-6 alone would not fully describe the small-infarct stratum, because uPA decreased while TWEAK and HGF increased. The targeted panel therefore adds biological detail to the biomarker results, but it does not establish a causal sequence from myocardial injury to any individual protein change. IL-6 is best read here as a candidate target raised by the observed association with larger infarcts, not as evidence that IL-6-directed treatment was tested or beneficial in this cohort. The findings are useful for framing hypotheses about size-stratified inflammatory signatures after type 1 myocardial infarction. (pmid:42373877)

Limitations

The study was exploratory and observational, with 70 participants from a single participating center and inclusion limited to patients with complete inflammatory biomarker assessments. These features limit how confidently the observed associations can be generalized beyond this cohort. Because peak CK was used as a surrogate for infarct size, the analysis did not directly compare the biomarker patterns with an imaging-derived infarct-size measure. (pmid:42373877)

The findings show associations and temporal patterns, not proof that infarct size caused the observed changes in IL-6, CRP, uPA, TWEAK, HGF, or other panel proteins. The targeted 96-protein inflammation panel also cannot represent all proteins in the circulating proteome. Finally, the study did not test whether targeting IL-6 improves outcomes; its therapeutic relevance remains a hypothesis generated by the observed pattern rather than a treatment result. (pmid:42373877)

Evidence boundary

This one-source briefing is limited to what the cited study reports. It does not establish independent confirmation, broader clinical effectiveness, or patient-specific guidance. The design, population, measurements, and follow-up described in that source define the evidence boundary. This summary provides research context and is not medical advice. The evidence should be read as a bounded report of the study rather than as a conclusion about other populations, settings, interventions, or outcomes. Any possible connection to disease mechanisms remains limited to the measurements and interpretations documented by the cited authors. Terms describing associations, responses, or biological patterns retain the meaning and uncertainty given in that source.

No inference beyond the cited source is made here.